[go: up one dir, main page]

IL139811A0 - Cell adhesion-inhibiting antinflammatory compounds - Google Patents

Cell adhesion-inhibiting antinflammatory compounds

Info

Publication number
IL139811A0
IL139811A0 IL13981199A IL13981199A IL139811A0 IL 139811 A0 IL139811 A0 IL 139811A0 IL 13981199 A IL13981199 A IL 13981199A IL 13981199 A IL13981199 A IL 13981199A IL 139811 A0 IL139811 A0 IL 139811A0
Authority
IL
Israel
Prior art keywords
inhibiting
cell adhesion
antinflammatory
compounds
antinflammatory compounds
Prior art date
Application number
IL13981199A
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of IL139811A0 publication Critical patent/IL139811A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pain & Pain Management (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL13981199A 1998-06-04 1999-06-03 Cell adhesion-inhibiting antinflammatory compounds IL139811A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9070198A 1998-06-04 1998-06-04
PCT/US1999/012419 WO1999062908A2 (en) 1998-06-04 1999-06-03 Cell adhesion-inhibiting antinflammatory compounds

Publications (1)

Publication Number Publication Date
IL139811A0 true IL139811A0 (en) 2002-02-10

Family

ID=22223903

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13981199A IL139811A0 (en) 1998-06-04 1999-06-03 Cell adhesion-inhibiting antinflammatory compounds

Country Status (15)

Country Link
EP (1) EP1090009A2 (en)
JP (1) JP2002517396A (en)
KR (1) KR20010052570A (en)
CN (1) CN1332743A (en)
AU (1) AU4231299A (en)
BG (1) BG105109A (en)
BR (1) BR9910864A (en)
CA (1) CA2333770A1 (en)
HU (1) HUP0102366A2 (en)
IL (1) IL139811A0 (en)
NO (1) NO20006157L (en)
PL (1) PL345906A1 (en)
SK (1) SK18542000A3 (en)
TR (1) TR200100189T2 (en)
WO (1) WO1999062908A2 (en)

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
CA2320730A1 (en) * 1998-12-23 2000-07-06 Renhua Li Thrombin or factor xa inhibitors
KR20010102543A (en) 1999-03-09 2001-11-15 로렌스 티. 마이젠헬더 4-Oxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carboxamides as Antiviral Agents
EP1181296A1 (en) * 1999-06-03 2002-02-27 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
EE04813B1 (en) * 1999-06-23 2007-04-16 Aventis Pharma Deutschland Gmbh Substituted Benzimidazoles, Their Preparation and their Use in the Preparation of a Drug for the Prophylaxis and Treatment of Diseases Due to Increased NFkB Activity
US6689883B1 (en) 1999-09-28 2004-02-10 Bayer Pharmaceuticals Corporation Substituted pyridines and pyridazines with angiogenesis inhibiting activity
JP2003522759A (en) * 2000-02-09 2003-07-29 ザ プロクター アンド ギャンブル カンパニー 2-carboxamide-benzimidazoles
US7977333B2 (en) 2000-04-20 2011-07-12 Bayer Healthcare Llc Substituted pyridines and pyridazines with angiogenesis inhibiting activity
DE60233823D1 (en) 2001-07-27 2009-11-05 Curis Inc N AND RELEVANT USES
BR0211214A (en) 2001-08-30 2004-07-13 Upjohn Co 4-thioxo-4,7-dihydro-thieno [2,3-b] pyridine-5-carboxamides as antiviral agents
WO2003020728A1 (en) 2001-08-30 2003-03-13 Pharmacia & Upjohn Company 4-THIOXO-4,7-DIHYDRO-THIENO[2,3-b]PYRIDINE-5-CARBOTHIOAMIDES AS ANTIVIRAL AGENTS
AR038117A1 (en) 2002-01-14 2004-12-29 Upjohn Co ANTIVIRAL AGENTS DERIVED FROM 4- OXO-4,7 -DIHYDROFIDE [2,3-B] PIRIDIN-5-CARBOXAMIDA
AR038294A1 (en) 2002-01-14 2005-01-12 Upjohn Co OXOTIENE (3,2-B) PYRIDINCARBOXAMIDS AS ANTIVIRAL AGENTS
AR038118A1 (en) 2002-01-14 2004-12-29 Upjohn Co COMPOUNDS DERIVED FROM ACID BENCINAMIDE 7-OXO-4,7-DIHIDROTIEN [2,3-B [PIRIDIN-6-CARBOXYLIC 3-REPLACED WHICH ARE USEFUL AS ANTIVIRAL
AU2003299472A1 (en) * 2002-05-06 2004-07-22 Vertex Pharmaceuticals Incorporated Thiadiazoles or oxadiazoles and their use as inhibitors of JAK kinase
JP2005538118A (en) 2002-08-06 2005-12-15 アストラゼネカ アクチボラグ Condensed pyridine and pyrimidine with TIE2 (TEK) activity
IL154306A0 (en) * 2003-02-05 2003-09-17 Rimonyx Pharmaceuticals Ltd Pharmaceutical compositions comprising thieno [2,3-c] pyridine derivatives and use thereof
AU2005238178A1 (en) * 2004-05-04 2005-11-10 F. Hoffmann-La Roche Ag Thienopyridazines as IKK inhibitors
KR100796965B1 (en) * 2004-05-04 2008-01-22 에프. 호프만-라 로슈 아게 Thienopyridine as Ib Inhibitor
WO2005110410A2 (en) * 2004-05-14 2005-11-24 Abbott Laboratories Kinase inhibitors as therapeutic agents
RU2007101509A (en) 2004-06-17 2008-07-27 Уайт (Us) METHOD FOR PRODUCING HORMONE RECEPTOR ANTAGONISTS RELEASING GONADOTROPINE
AU2005264996A1 (en) 2004-06-17 2006-01-26 Wyeth Gonadotropin releasing hormone receptor antagonists
RU2007107167A (en) 2004-07-30 2008-09-10 Метилджин, Инк. (Ca) VEGF RECEPTOR AND HGF RECEPTOR SIGNAL INHIBITORS
TW200615268A (en) 2004-08-02 2006-05-16 Osi Pharm Inc Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
WO2006047397A1 (en) * 2004-10-21 2006-05-04 Dow Agrosciences Llc Thieno-pyrimidine compounds having fungicidal activity
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
US7674822B2 (en) 2004-11-24 2010-03-09 Wyeth PTP1b inhibitors
AR054416A1 (en) 2004-12-22 2007-06-27 Incyte Corp PIRROLO [2,3-B] PIRIDIN-4-IL-AMINAS AND PIRROLO [2,3-B] PIRIMIDIN-4-IL-AMINAS AS INHIBITORS OF THE JANUS KINASES. PHARMACEUTICAL COMPOSITIONS.
US7534796B2 (en) 2005-02-18 2009-05-19 Wyeth Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
US7582634B2 (en) 2005-02-18 2009-09-01 Wyeth 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7538113B2 (en) 2005-02-18 2009-05-26 Wyeth 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7531542B2 (en) 2005-05-18 2009-05-12 Wyeth Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
CA2611370C (en) 2005-05-20 2014-11-25 Oscar Mario Saavedra Inhibitors of vegf receptor and hgf receptor signaling
MX2007014617A (en) 2005-05-20 2008-02-11 Methylgene Inc Inhibitors of vegf receptor and hgf receptor signaling.
US7582636B2 (en) 2005-05-26 2009-09-01 Wyeth Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
CN102127078A (en) 2005-07-14 2011-07-20 安斯泰来制药株式会社 Heterocyclic janus kinase 3 inhibitors
WO2007007919A2 (en) 2005-07-14 2007-01-18 Astellas Pharma Inc. Heterocyclic janus kinase 3 inhibitors
EP2308852A1 (en) 2005-08-21 2011-04-13 Abbott GmbH & Co. KG 5-ring heteroaromatic compounds and their use as binding partners for 5-HT5 receptors
EP2270014A1 (en) 2005-09-22 2011-01-05 Incyte Corporation Azepine inhibitors of janus kinases
RS54181B9 (en) 2005-12-13 2020-01-31 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
AR059898A1 (en) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv DERIVATIVES OF 3-CIANO-PIRIDONA 1,4-DISUSTITUTED AND ITS USE AS ALLOSTERIC MODULATORS OF MGLUR2 RECEIVERS
JP5606734B2 (en) 2006-04-25 2014-10-15 アステックス、セラピューティックス、リミテッド Pharmaceutical compounds
US8227603B2 (en) 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
PL2583970T3 (en) 2006-08-02 2016-05-31 Cytokinetics Inc Certain chemical entities, compositions and methods comprising imidazopyrimidines
ES2415863T3 (en) 2006-12-22 2013-07-29 Incyte Corporation Substituted heterocycles as Janus Kinase inhibitors
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
EP2139478A4 (en) 2007-03-30 2010-05-05 Cytokinetics Inc Certain chemical entities, compositions and methods
CL2008001709A1 (en) 2007-06-13 2008-11-03 Incyte Corp Compounds derived from pyrrolo [2,3-b] pyrimidine, jak kinase modulators; pharmaceutical composition; and use in the treatment of diseases such as cancer, psoriasis, rheumatoid arthritis, among others.
CN101932582B (en) 2007-06-13 2013-09-25 因塞特公司 Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
CA2697399C (en) 2007-09-14 2016-01-19 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
CN103342695B (en) 2007-09-14 2015-04-22 杨森制药有限公司 1',3'-disubstituted-4-pheny-3,4,5,6-tetrahydro-2H,1'H-[1,4']bipyridinyl-2'-ones
ME01999B (en) 2007-10-11 2015-05-20 Astrazeneca Ab Pyrrolo[2, 3 -d]pyrimidin derivatives as protein kinase b inhibitors
BRPI0820544A2 (en) 2007-11-16 2015-06-16 Incyte Corp 4-pyrazolyl-n-arylpyrimidin-2-amines and pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
EP2247588B1 (en) 2008-02-26 2016-04-13 Takeda Pharmaceutical Company Limited Fused heterocyclic derivative and use thereof
CN102015723B (en) 2008-03-05 2014-07-30 梅特希尔基因公司 Inhibitors of protein tyrosine kinase activity
DK2288610T3 (en) 2008-03-11 2016-11-28 Incyte Holdings Corp Azetidinesulfonic AND CYCLOBUTANDERIVATER AS JAK INHIBITORS
JP2011518836A (en) 2008-04-24 2011-06-30 インサイト・コーポレイション Macrocycles and their use as kinase inhibitors
ES2439291T3 (en) 2008-09-02 2014-01-22 Janssen Pharmaceuticals, Inc. 3-Azabicyclo [3.1.0] hexyl derivatives as modulators of metabotropic glutamate receptors
ES2401691T3 (en) 2008-11-28 2013-04-23 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzoxacin derivatives as modulators of metabotropic glutamate receptors
WO2010085597A1 (en) 2009-01-23 2010-07-29 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
BRPI1010831A2 (en) 2009-05-12 2016-04-05 Addex Pharmaceuticals Sa 1,2,4-triazolo [4,3-a] pyridine derivatives and their as positive allosteric modulators of mglur2 receptors
SG176021A1 (en) 2009-05-12 2011-12-29 Janssen Pharmaceuticals Inc 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
TWI484962B (en) 2009-05-22 2015-05-21 Incyte Corp 3-[4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane or heptonitrile as a JAK inhibitor
AR076794A1 (en) 2009-05-22 2011-07-06 Incyte Corp DERIVATIVES OF N- (HETERO) ARIL-PIRROLIDINA DE PIRAZOL-4-IL-PIRROLO [2,3-D] PIRIMIDINES AND PIRROL-3-IL-PIRROLO [2,3-D] PYRIMIDINS AS INHIBITORS OF THE JANUS KINASE AND COMPOSITIONS PHARMACEUTICS THAT CONTAIN THEM
WO2010151317A1 (en) 2009-06-22 2010-12-29 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
EP2445340B1 (en) 2009-06-22 2016-05-18 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
US9249145B2 (en) 2009-09-01 2016-02-02 Incyte Holdings Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
PL2486041T3 (en) 2009-10-09 2014-01-31 Incyte Holdings Corp Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
KR101911697B1 (en) 2010-03-10 2018-10-25 인사이트 홀딩스 코포레이션 Piperidin-4-yl azetidine derivatives as jak1 inhibitors
KR102040479B1 (en) 2010-05-21 2019-11-06 인사이트 홀딩스 코포레이션 Topical formulation for a jak inhibitor
CN102260270A (en) * 2010-05-28 2011-11-30 中国科学院上海药物研究所 N-(2-methylfuran[2,3-d]pyrimidine-4-yl)acrylamide, its preparation method and application
EP2643320B1 (en) 2010-11-08 2015-03-04 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
CN103298809B (en) 2010-11-08 2016-08-31 杨森制药公司 1,2,4-triazol [4,3-a] pyridine derivate and the purposes of the positive allosteric modulators as MGLUR2 acceptor thereof
CA2814996C (en) 2010-11-08 2019-10-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
NZ611151A (en) 2010-11-19 2015-06-26 Incyte Corp Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
JP5917544B2 (en) 2010-11-19 2016-05-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Heterocyclic substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
WO2012088015A2 (en) 2010-12-22 2012-06-28 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
EP2675451B9 (en) 2011-02-18 2017-07-26 Novartis Pharma AG mTOR/JAK INHIBITOR COMBINATION THERAPY
AU2012235902B2 (en) 2011-04-01 2015-08-27 Astrazeneca Ab Therapeutic treatment
MY165963A (en) 2011-06-20 2018-05-18 Incyte Holdings Corp Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
CN103732596B (en) 2011-07-08 2016-06-01 诺华股份有限公司 Pyrrolopyrimidine derivatives
SG10201605707UA (en) 2011-07-13 2016-09-29 Cytokinetics Inc Combination als therapy
JP2014521725A (en) 2011-08-10 2014-08-28 ノバルティス・ファルマ・アクチェンゲゼルシャフト JAKPI3K / mTOR combination therapy
TW201313721A (en) 2011-08-18 2013-04-01 Incyte Corp Cyclohexyl azetidine derivatives as JAK inhibitors
UA111854C2 (en) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн METHODS AND INTERMEDIATE COMPOUNDS FOR JAK INHIBITORS
SG11201401471PA (en) 2011-11-30 2014-08-28 Astrazeneca Ab Combination treatment of cancer
DK2797416T3 (en) 2011-12-28 2017-10-30 Global Blood Therapeutics Inc SUBSTITUTED BENZALDEHYD COMPOUNDS AND METHODS OF USING THEM IN INCREASED TISSUE OXIDATION
EP2797597B1 (en) 2011-12-28 2020-02-26 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
TW201406761A (en) 2012-05-18 2014-02-16 Incyte Corp Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
BR112015010663B1 (en) 2012-11-15 2022-12-06 Incyte Holdings Corporation SUSTAINED RELEASE ORAL DOSAGE FORMS AND USE OF RUXOLITINIB OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
BR112015021458B1 (en) 2013-03-06 2022-06-07 Incyte Holdings Corporation "PROCESSES AND INTERMEDIARIES FOR PREPARING {1-{1-[3-FLUORINE2-(TRIFLUORMETHYL)ISONICOTINOYL] PIPERIDIN-4-IL}-3-[4-(7HPIRROLO[2,3-D]PYRIMIDIN-4-IL)- 1H-PYRAZOL-1-IL]AZETIDIN-3-YL}ACETONITRILE, USEFUL IN THE TREATMENT OF DISEASES RELATED TO THE ACTIVITY OF JANUS KINASES
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
WO2014145040A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
ES2890077T3 (en) 2013-03-15 2022-01-17 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
AU2014237330A1 (en) 2013-03-15 2015-09-17 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US20140274961A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EA034922B1 (en) 2013-03-15 2020-04-07 Глобал Блад Терапьютикс, Инк. Compounds and uses thereof for the modulation of hemoglobin
JO3368B1 (en) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv 6, 7- dihydropyrazolu [5,1-a] pyrazine-4 (5 hands) -on compounds and their use as negative excretory regulators of Miglore 2 receptors.
AU2014305989B2 (en) 2013-08-07 2019-11-28 Incyte Holdings Corporation Sustained release dosage forms for a JAK1 inhibitor
JO3367B1 (en) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv 1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
EA202092627A1 (en) 2013-11-18 2021-09-30 Глобал Блад Терапьютикс, Инк. COMPOUNDS AND THEIR APPLICATIONS FOR HEMOGLOBIN MODULATION
BR112016011727A2 (en) 2013-11-22 2017-08-08 CL BioSciences LLC GASTRIN ANTAGONISTS FOR THE TREATMENT AND PREVENTION OF OSTEOPOROSIS
HRP20191646T1 (en) 2014-01-21 2019-12-13 Janssen Pharmaceutica Nv COMBINATIONS CONTAINING POSITIVE ALOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR SUBTYPE 2 AND THEIR USE
SMT202100103T1 (en) 2014-01-21 2021-03-15 Janssen Pharmaceutica Nv COMBINATION COMPRISING POSITIVE ALLOSTERIC MODULATORS OF THE METABOTROPIC GLUTAMATE RECEPTOR SUBTYPE 2 AND THEIR USE
FI3102208T4 (en) 2014-02-07 2024-09-23 Global Blood Therapeutics Inc Crystalline polymorph of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
MA41841A (en) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc ALDEHYDE COMPOUNDS FOR THE TREATMENT OF PULMONARY FIBROSIS, HYPOXIA, AND AUTOIMMUNE AND CONNECTIVE TISSUE DISEASES
US11020382B2 (en) 2015-12-04 2021-06-01 Global Blood Therapeutics, Inc. Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
TWI825524B (en) 2016-05-12 2023-12-11 美商全球血液治療公司 Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1hpyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
CN107513067A (en) 2016-06-16 2017-12-26 北京赛林泰医药技术有限公司 Pyrrolopyrimidine compounds containing substituted cyclopenta
US10154992B2 (en) * 2016-07-12 2018-12-18 The Regents Of The University Of California Compounds and methods for treating HIV infection
JOP20190024A1 (en) 2016-08-26 2019-02-19 Gilead Sciences Inc Substituted pyrrolizine compounds and uses thereof
TW202332423A (en) 2016-10-12 2023-08-16 美商全球血液治療公司 Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
AR113922A1 (en) 2017-12-08 2020-07-01 Incyte Corp LOW DOSE COMBINATION THERAPY FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS
LT3746429T (en) 2018-01-30 2022-05-10 Incyte Corporation (1- (3-FLUORO-2- (TRIFLUORMETHYL) ISONICOTINYL) PIPERIDIN-4-ONO)
CN111788204B (en) 2018-02-26 2023-05-05 吉利德科学公司 Substituted pyrrolizine compounds as inhibitors of HBV replication
CA3095487A1 (en) 2018-03-30 2019-10-03 Incyte Corporation Treatment of hidradenitis suppurativa using jak inhibitors
ES2966707T3 (en) 2018-10-01 2024-04-23 Global Blood Therapeutics Inc Hemoglobin modulators for the treatment of sickle cell disease
CN113874015B (en) 2018-12-21 2024-05-24 细胞基因公司 Thienopyridine inhibitors of RIPK2
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3903095A (en) * 1972-02-18 1975-09-02 Merck & Co Inc Certain substituted-thieno{8 3,2-c{9 -pyridines
AR208500A1 (en) * 1972-06-14 1977-02-15 Merck & Co Inc PROCEDURE FOR THE PREPARATION OF OXAZOLE (4,5-B) -PYRIDINES DERIVATIVES
FR2334356A1 (en) * 1975-12-10 1977-07-08 Parcor Thieno pyridines and salts - having sedative, antiinflammatory, analgesic and platelet aggregation-inhibiting activity
FR2336132A1 (en) * 1975-12-23 1977-07-22 Parcor Antiinflammatory thieno-indolizines - also with blood platelet aggregation inhibitory activity
FR2411838A1 (en) * 1977-12-19 1979-07-13 Parcor NEW DERIVATIVES OF THIENO (2-3-C) AND (3,2-C) PYRIDINES, THEIR PREPARATION PROCESS AND THEIR THERAPEUTIC APPLICATION
FR2452490A1 (en) * 1979-03-30 1980-10-24 Sanofi Sa 2-Hydroxy-3-aminopropoxy thieno-pyridine derivs. - useful as antiinflammatories, beta blockers and antiarrhythmics for human and veterinary medicine
DE3533331A1 (en) * 1985-09-18 1987-03-26 Heumann Ludwig & Co Gmbh Pyridothiazole derivatives, process for their preparation, and medicaments containing these compounds
US4804658A (en) * 1986-09-15 1989-02-14 G. D. Searle & Co. Imidazopyridine derivatives and pharmaceutical compositions
GB8712747D0 (en) * 1987-05-30 1987-07-01 Pfizer Ltd Therapeutic agents
MY104933A (en) * 1987-09-30 1994-07-30 Pfizer Ltd Platelet activating factor antagonists
US5227384A (en) * 1988-03-14 1993-07-13 G. D. Searle & Co. 5-substituted [4,5-c] imidazopyridines and pharmaceutical use thereof
EP0404797B1 (en) * 1988-03-15 1995-02-01 G.D. Searle & Co. 1H/3H-[4-(N,N-CYCLOALKYL AND/OR BRANCHED-ALKYLCARBOXAMIDO) -BENZYL]IMIDAZO[4,5-c]PYRIDINES AS PAF ANTAGONISTS
CA2012716A1 (en) * 1989-03-22 1990-09-22 Akito Tanaka Thiazole compounds, processes for the preparation thereof and pharmaceutical composition comprising the same
US4988707A (en) * 1989-09-13 1991-01-29 G. D. Searle & Co. Pharmacologically active phenylalkanoyl substituted imidazo (4,5-C) pyridines
US5585492A (en) * 1994-10-11 1996-12-17 G. D. Searle & Co. LTA4 Hydrolase inhibitors
CA2268126A1 (en) * 1996-11-06 1998-05-14 Hazel Joan Dyke Quinolines and their therapeutic use

Also Published As

Publication number Publication date
WO1999062908A3 (en) 2000-03-30
TR200100189T2 (en) 2001-05-21
PL345906A1 (en) 2002-01-14
HUP0102366A2 (en) 2001-11-28
JP2002517396A (en) 2002-06-18
KR20010052570A (en) 2001-06-25
CN1332743A (en) 2002-01-23
WO1999062908A2 (en) 1999-12-09
AU4231299A (en) 1999-12-20
BR9910864A (en) 2002-02-05
NO20006157L (en) 2001-02-02
CA2333770A1 (en) 1999-12-09
EP1090009A2 (en) 2001-04-11
BG105109A (en) 2001-11-30
NO20006157D0 (en) 2000-12-04
SK18542000A3 (en) 2001-12-03

Similar Documents

Publication Publication Date Title
PL345906A1 (en) Cell adhesion-inhibiting antinflammatory compounds
EP0971430A4 (en) Battery
HUP0103564A3 (en) Electrochemical cell
GB2333190B (en) Cell array circuitry
GB9817575D0 (en) Pack
GB0017742D0 (en) New case
GB9807774D0 (en) Electrochemical cell
GB2339221B (en) Unplanar non-axisymetric inserts
GB9809964D0 (en) Electrochemical cell
GB9817578D0 (en) Pack
TW395202U (en) Carrying case
GB9821921D0 (en) Power cell
GB9815169D0 (en) Electrolytic cell
EP0969542A4 (en) Battery
GB9802157D0 (en) Consa pack
GB9805817D0 (en) Battery
GB0028736D0 (en) Separator for enclosed cell
GB9816443D0 (en) Electrochemical cell
HK1035898A (en) Cell adhesion-inhibiting a antinflammatory compounds
PL347221A1 (en) Flotation cell line
GB9816444D0 (en) Electrochemical cell
ZA981740B (en) Photovoitaic cell
GB9815827D0 (en) Battery
GB9810076D0 (en) Cell processor
GB9801470D0 (en) Cell line